Chemo Triumphs in Second-Line Metastatic Prostate Cancer
‘Practice-changing’ results show that cabazitaxel is superior to androgen-signaling inhibitors in second-line treatment of metastatic castrate-resistant prostate cancer.
Related Articles
BTK Inhibitors for Chronic Lymphocytic Leukemia: Pharmacist Viewpoints
Join us for a CPE-certified live social media event, providing instant engagement with top pharmacy experts in chronic lymphocytic leukemia (CLL) management….
Prostate Cancer Highlights: Expert Review of European Oncology Meeting
In this CME-accredited, live, and interactive social media event, a panel of 3 oncology experts will review key emerging prostate cancer data released at the…
A Guideline-based Care Model for Endometrial Cancer in the Adjuvant Setting
Join these gynecologic oncology experts in a live social media event to hear the latest endometrial cancer clinical practice guidelines and key studies that …
MDT Care in Endometrial Cancer: Responsibilities of the Care Team
Join Medscape Oncology for a live interactive social media event on themultidisciplinary care for patients with endometrial cancer. Our multidisciplinarypane…
BTK Inhibitors for Chronic Lymphocytic Leukemia: Pharmacist Viewpoints
Join us for a CPE-certified live social media event, providing instant engagement with top pharmacy experts in chronic lymphocytic leukemia (CLL) management….
BTK Inhibitors for Chronic Lymphocytic Leukemia: Pharmacist Viewpoints
Other event by Medscape on Wednesday, September 25 2024